跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.

首页临床试验发起方与机构Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.

Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.

Oberlaaer Straße 235, Wien, 奥地利

别名:

octapharma pharmazeutika produktionsges.m.b.h.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

34

32 进行中

药物批准

25

批准总数

监管机构

5

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

32

94.1%

3 期

1

2.9%

试验状态分布

进行中（未招募）

32

94.1%

已完成

1

2.9%

招募中

1

2.9%

相关临床试验

该机构主办的试验（34）

Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective phase III clinical study to evaluate the efficacy and safety of Panzyga in infection prevention in patients with a specific type of cancer, cancer of the blood and bone marrow (Chronic Lymphocytic Leukemia) (PRO-SID study)

进行中（未招募）

Apr 2023450 名受试者

Double-blind (neither the patient nor the doctor knows treatment allocation of the patient), randomized, placebo-controlled, prospective phase III clinical study to evaluate the efficacy and safety of Panzyga in infection prevention in patients with a specific type of cancer, cancer of the blood and bone marrow (Chronic Lymphocytic Leukemia) (PRO-SID study)

进行中（未招募）

Dec 2022450 名受试者

Clinical study to find out how well wilate works in little children with severe von Willebrand disease

进行中（未招募）

Aug 202212 名受试者

A Phase III Study to Compare the Effect of Panzyga and Placebo in Patients with PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome)

进行中（未招募）

Aug 202292 名受试者

Clinical study to find out how well wilate works in little children with severe von Willebrand disease

Jul 202212 名受试者

A Phase III, randomized, double-blind, multicenter study to assess the efficacy and safety of OCTAPLEX, a four-factor prothrombin complex concentrate (4F-PCC), compared to the 4F-PCC Beriplex® P/N (Kcentra), for the reversal of vitamin K antagonist induced anticoagulation in patients needing urgent surgery with significant bleeding risk.

进行中（未招募）

May 2022370 名受试者

DOUBLE-BLIND, RANDOMIZED, PLACEBO- CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS.

进行中（未招募）

May 20221 名受试者

Study To Compare The Effect of Panzyga compared to Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome.

进行中（未招募）

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

2

药物批准

FDA

Food and Drug Administration

8

药物批准

PHILIPPINES

Philippines FDA

2

药物批准

SFDA

Saudi Food and Drug Authority

3

药物批准

NPRA

National Pharmaceutical Regulatory Agency

10

药物批准

近期批准

Octagam 10%, Solution for Infusion

Albunorm 25%, 250 g/l, Solution for Infusion

Albunorm 5%, 50 g/l, Solution for Infusion

OCTANATE 100IU/ML INJECTION

Albunorm 20%, 200 g/l, Solution for Infusion

OCTANINE F LYOPHILLISED POWDER FOR INTRAVENOUS ADMINISTRATION

OCTANATE 50IU/ML INJECTION

Octaplex Powder and Solvent for Solution for Infusion

WILATE 500 IU Powder and Solvent for Solution for Injection

资讯

暂无资讯文章

本页目录

概览
相关临床试验34
药物批准25
资讯

返回机构列表